Cargando…
Adjuvant Therapy in Renal Cell Carcinoma—Past, Present, and Future()
To date, no effective adjuvant treatment for renal cell carcinoma (RCC) has been described, but research in this area is important since the 5-year relapse rate for intermediate- and high-risk early-stage RCC is 30%–40%. Metastatic RCC can be treated successfully with immune therapy and targeted the...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
W.B. Saunders
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3765962/ https://www.ncbi.nlm.nih.gov/pubmed/23972712 http://dx.doi.org/10.1053/j.seminoncol.2013.05.004 |